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Ménière's disease (MD) is an idiopathic pathological condition of the inner ear, most often unilateral, caused by endolymphatic hydrops, which leads to symptoms such as fluctuating hearing loss, tinnitus and fullness, associated with recurrent episodes of rotational vertigo with neurovegetative symptoms ^[@ref1]^. The current prevalence of the disease is 190/100,000 ^[@ref2]^. There is discordance regarding the gender-distribution of the disease: some authors report a higher prevalence in men ^[@ref3]^, while others described a higher prevalence in women ^[@ref4]^; there is general agreement that MD is a disease of middle-age, with average age at onset in the fourth decade of life ^[@ref2]^. A controversial feature of the disease is represented by possible bilateral involvement, especially during the natural progression of MD. The literature on this aspect provides extremely heterogeneous data, with percentages of bilateral involvement ranging from 2% to 78% of patients ^[@ref5]^. This broad range might depend on the definition of bilateral involvement, given that hearing abnormalities, without the appearance of complete symptomatology of MD, are frequently found in the contralateral ear ^[@ref6]^.

Various treatment strategies have been proposed and used for MD, most of which are based on empirical criteria. Some of these therapies are widely accepted, while others are only practiced in a few centres. The differences in treatments is due to the lack of a definite aetiopathogenesis of the disease, as well as to the difficulty of carrying out clinical class A studies, given the natural fluctuation of the disease which includes long phases of remission. Reviews that analyse the response of MD patients to various therapies have reported that the success rate, roughly 70%, was not different from that obtained with placebo treatments ^[@ref7]^. Nevertheless, based on clinical pragmatism, medical treatment is the first therapeutic option for MD, taking into account cost-effectiveness and potential side effects. If a positive response to therapy is not obtained, more specific treatments may be considered. Medical treatment for MD has two components: treatment of acute attacks and prophylaxis between attacks. In the treatment of acute vertigo attacks, vestibular suppressants (i.e. dimenhydrinate, meclizine) are usually associated with antiemetic drugs. Diazepam, which has an additional beneficial anxiolytic effect, might also be administered intravenously. Steroid treatment in the acute phase, initially suggested because of the hypothesised autoimmune origin of MD, has been used to reduce the magnitude of crises as well as to promote auditory and vestibular recovery ^[@ref8]^. Corticosteroids (e.g. prednisone 1 mg/kg) can be used both intravenously and orally in cycles of 10-14 days. Finally, osmotic diuretics (10% mannitol or glycerol) given intravenously as a slow infusion may also be used as treatment.

Treatment prescribed for the intercritical phase aims to: (i) reduce the number and severity of vertiginous crises; (ii) relieve chronic symptoms (instability and tinnitus); and (iii) prevent progression of the disease, with specific focus on hearing loss and loss of equilibrium. Maintenance therapies are able to achieve sufficient control of vertiginous crises in at least two-thirds of patients, especially when associated with a healthy lifestyle (i.e., no alcohol, no tobacco, no coffee, no stress), dietary measures (sodium restriction) and diuretics ^[@ref9]^; however, there is no effective therapy for long-term hearing preservation.

The most widely used drug for MD in Europe is betahistine, a histamine-like molecule that acts as a weak agonist for the H1 receptor and, at the same time, as an effective antagonist for the H3 receptor ^[@ref10]^. Betahistine was first registered in 1968 and is widely used in the management of vertigo. Although its mechanism of action is only partially known, several different potential effects based on both preclinical and clinical studies have been suggested. Firstly, betahistine modulates histaminergic neurotransmission through partial agonist action at the histamine H1 receptor, combined with potent histamine H3 antagonistic properties. Secondly, betahistine has been reported to have vascular effects in both the cochlea and brain ^[@ref11]^. Thirdly, betahistine is thought to have effects on neuronal excitability, with a dose-dependent inhibiting effect on spike generation of neurons in lateral and medial vestibular nuclei ^[@ref15][@ref16]^. It is possible that the anti-vertigo activity of betahistine is first achieved by the drug itself, and then sustained by aminoethylpyridine, one of its metabolites ^[@ref17]^. Finally, the available evidence suggests that the histamine H3 receptor plays a key role in vestibular compensation, behavioural recovery and reduction of symptoms. Betahistine may potentially act on recovery mechanisms to provide clinical benefits by helping to improve behavioural adaptation ^[@ref10]^. Taken together, these properties are thought to contribute to the beneficial therapeutic effects of betahistine in MD and vestibular vertigo. Although the effect of betahistine on vertigo has been assessed in many studies, it remains uncertain to what extent the compound improves symptomatology in MD and vestibular vertigo. In the past decade, only one systematic review ^[@ref18]^ and one meta-analysis ^[@ref19]^ were published on this topic, showing no strong evidence about the positive effects of betahistine MD. These inconclusive findings might be attributable to the methodology chosen to perform the analysis ^[@ref20]^. Thus, there is not sufficient evidence for any of the proposed treatments for the management of MD to be considered effective, and although several studies have been conducted, the results are inconclusive and inconsistent ^[@ref21]^.

Methods {#sec1-2}
=======

In order to define adequate best practice criteria in MD therapy, we began with a rigorous and systematic analysis of the literature, identifying all studies on betahistine in MD. We evaluated the statistical methodology, selection criteria of patients, searching for possible biases, and determined whether a possible conflict of interest was present. Since most of the studies on betahistine were biased or inconclusive, we decided to consider expert opinion as the method of choice for clinical decision, organising a Consensus Conference (CC) with experts in the field. A CC is a series of meetings to collect opinions and decisions on new or controversial topics in science, technology and ethics, and is a useful and effective tool to synthesise current knowledge and address uncertainties ^[@ref22]^.

The CC on betahistine in MD involved a group of 78 Italian experts on vestibular disorders (see [appendix](#app001){ref-type="app"}), who were asked a series of questions specifically prepared by 13 opinion leaders. The opinion leader group (research team) consisted in Otolaryngologists or Audiologists with special expertise in Ménière's disease. After the questions had been formulated, selected articles were circulated to all participants, who reported their comments on a form. For each, two separate experts prepared respective statements. For controversial issues, for which no answer was found in the literature, new statements were prepared and discussed.

Delphi method and statement generation {#sec2-1}
--------------------------------------

To increase consensus, the CC was based on the Delphi method ^[@ref23]^. The Delphi method is an iterative investigation method, which through several stages of evaluation aims to reach the most comprehensive opinion, shared in a single statement; the Delphi method allows to systematically obtain responses to a problem from a panel of independent experts in two or three rounds with a consensus-based approach. After each round, an administrator provides a summary of the experts' answers and their rationale. The process ends when the experts' answers vary only slightly between rounds. Starting from the above-mentioned systematic review of the literature, the opinion leader group created for the panelists, relevant statements about specific scenarios associated with the employment of betahistine in Ménière's disease.

During the CC event (single day meeting in Rome on December 12^th^ 2015), a tele-voting system allowed each participant to anonymously evaluate all statements on a Likert 5-point scale. The answers associated with 1 and 2 of the scale were considered as a "NO", while 3, 4 and 5 were counted as "YES". Following the literature on the Delphi method, a statement was considered accepted when 70% agreement on "YES" or on "NO" was reached. [Figure 1](#fig001){ref-type="fig"} show the process of acquisition of data from the CC.

Results {#sec1-3}
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The entire panel of 78 Italian experts in vestibular disorders participated in the CC and evaluated the use and efficacy of betahistine in MD. With regards to prevention of vertigo spells, betahistine was considered useful (87% agreement) and a first-choice therapy between attacks (71% agreement, [Fig. 2](#fig002){ref-type="fig"}). However, betahistine was considered less effective during the acute phase of the disease and useful only when associated with other drugs (77% agreement, [Fig. 3](#fig003){ref-type="fig"}). In the management of Tumarkin's otolithic crisis, the drug was not considered efficacious (85% agreement), and useful only if associated with other agents (74% agreement). When surveyed about Tumarkin's otolithic crisis, 66% of experts had not found a useful dosage and did not rely on betahistine monotherapy to deal with this condition. The efficacy of the drug is low when used to prevent progressive auditory deterioration (82% agreement), tinnitus (79% agreement) and fullness (86% agreement).

Despite the statement affirming that betahistine is not useful during the acute phase, if the drug is used in this phase of the disease, the dosage range is between 32 and 48 mg/day (72% agreement, [Fig. 4](#fig004){ref-type="fig"}). On the contrary, 86% of experts agreed on the usefulness of the drug in the intercritical phase. While 81% of experts agreed that the dosage can vary during the different phases of the disease, the preferred overall dosage was between 32 and 48 mg/day (84% agreement, [Fig. 5](#fig005){ref-type="fig"}). The experts were also surveyed about the duration of treatment in relation to the number of Ménière's crises during a 6-month interval. The experts agreed on a 3-month treatment in cases of one to three crises per 6 months (82% agreement), while the preferred duration of treatment is 6 months (74% agreement) if a patient has 4 to 10 crises in 6 months. In cases with more than 10 crises, the appropriate duration of treatment was considered to be either 6 months (69% agreement) or one year (66% agreement). The efficacy of betahistine does not seem to depend on age: 84% of experts agreed that it can be used by adults of all ages indifferently and regardless of gender. As far as comorbid conditions and drug interactions are concerned, in patients with MD and migraine most of the experts surveyed would use betahistine in association with an anti-migraine drug (67% agreement). In cases of comorbidity with anxious-depressive disorders, betahistine can be given in association with an anti-depressant or anxiolytic (78% agreement). Betahistine was considered to be a safe drug, with the overall frequency of side effects judged to be less than 10% (90% agreement). Gastric disturbances are the only common side effects mentioned by patients (73% agreement). Overall, to evaluate the efficacy of betahistine, the experts took into account the number and severity of crises in the preceding 6 months (93% agreement), clinical assessment of the vestibule (67% agreement) and the patients' quality of life (85% agreement).

Discussion {#sec1-4}
==========

As previously discussed, the therapeutic strategies used for MD are varied and largely based on empirical criteria. The absence of a confirmed aetiopathogenesis, the difficulty in making a reliable diagnosis, together with the complexity of conducting clinical class A studies, explain the observed differences in treatments. In Europe, the most frequently prescribed drug, used mainly to reduce the frequency and severity of MD attacks, is betahistine, a weak H1 agonist and strong H3 antagonist histaminergic molecule ^[@ref10]^. Betahistine seems to have a dose-dependent role on neuronal excitability ^[@ref15][@ref16]^, as well as on cochlear and cerebral blood flow ^[@ref11][@ref24]^. In addition, its effects on H3 receptors seem to have a key role on vestibular compensation, favouring recovery and reduction of residual symptoms ^[@ref25]^.

Recent literature on the efficacy of betahistine in MD appears to be very discordant, and there is a marked lack of systematic reviews and meta-analyses. A recent Cochrane review concluded that betahistine is an acceptable treatment ^[@ref18]^. However, the authors did not find strong evidence for the efficacy of the drug in management of dizziness, tinnitus, loss of hearing, or fullness in MD. In contrast, a meta-analysis carried out by Della Pepa et al. ^[@ref19]^ found a role for the drug in the management of dizziness. According to a more recent meta-analysis, this lack of unequivocal evidence could be due to methodological limitations ^[@ref20]^. In that study, the authors concluded that betahistine can be considered as a safe drug, with a positive benefit/risk ratio, being effective in diseases for which dizziness and vertigo are the main symptoms. The consensus of experts consulted on betahistine, in light of their clinical practice and daily management of patients with MD, revealed a constant use of the drug during the intercritical phase, especially in monotherapy. Betahistine is considered to be safe, suitable for all age groups and associated with a low incidence of side effects (mainly gastrointestinal symptoms). These statements, based exclusively on the clinical experience of the consensus conference participants, seems to be confirmed by a very recent Cochrane review suggesting some positive effects of betahistine in reducing vertigo symptoms without any significant side effects ^[@ref26]^. Moreover, betahistine is successfully used with other drugs in cases of comorbidity with migraine and anxiety-depressive disorders ^[@ref27]^. During the intercritical phase, the dosage depends on the patient's response and phase of disease, but usually ranges from 32 to 48 mg/day. The duration of treatment varies, according to the frequency of crises, from a minimum of 3 months up to a maximum of 1 year. Clinical vestibular evaluation (history and symptoms of vestibular dysfunction) and the patient's quality of life during the disease are also taken into account when evaluating the efficacy of betahistine. Betahistine is not recommended for the acute phase of MD or for Tumarkin's otolithic crises (although it can have a role if associated with other drugs), and has been found to have low efficacy in the management of auditory deterioration, tinnitus and auricular fullness.

Conclusions {#sec1-5}
===========

The experts' clinical practice and personal experience support the use of betahistine in MD to reduce the number and severity of vertiginous crises, particularly during the intercritical phase of the disease. Betahistine does not show positive effects on auditory symptoms of MD, but its use seems to be at low risk of major side effects. However, clinical studies based on rigorous methodologies and outcome measures are needed to clearly evaluate the role of betahistine in the treatment of MD.
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